Eruptive Nevi Mimicking Wart-Like Lesions under Selective BRAF Inhibition in a 37-Year-Old Female Melanoma Patient

BACKGROUND: The BRAF inhibitor vemurafenib is state of the art in therapy of patients with malignant melanoma in non-resectable stage III or stage IV and evidence of oncogenetic BRAF mutation. Multiple cutaneous side effects like rash and keratoacanthoma-like lesions have been described so far. CASE...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmitt, Laurenz, Schumann, Tamara, Inhoff, Oliver, Löser, Christoph, Rebel, Martin, Dippel, Edgar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2013
Materias:
Published online: March, 2013
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3617885/
https://www.ncbi.nlm.nih.gov/pubmed/23626542
http://dx.doi.org/10.1159/000350288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3617885/
https://www.ncbi.nlm.nih.gov/pubmed/23626542
http://dx.doi.org/10.1159/000350288

Ejemplares similares